Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Venlafaxine is a synthetic small molecule antidepressant classified as a selective serotonin and norepinephrine reuptake inhibitor (SNRI). It is primarily used to treat major depressive disorder, generalized anxiety disorder, social anxiety disorder, and panic disorder in adults. Venlafaxine works by inhibiting the reuptake of serotonin at lower doses and both serotonin and norepinephrine at higher doses, increasing their levels in the brain to help maintain mental balance. It also has weak inhibitory effects on dopamine reuptake at high doses. The drug was first approved for use in 1993 (immediate-release) with an extended-release formulation introduced later[1][2][5][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on venlafaxine.